Palisade Bio (FRA:7NS0) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:7NS0 Palisade Bio Inc FRA:7NS0
35 GF Score
Price €5.01
! 2 Warning Signs
View Full Analysis

What is Palisade Bio OCF Margin %?

Palisade Bio FRA:7NS0 35 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:7NS0 with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Palisade Bio ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Palisade Bio's Cash Flow from Operations for the three months ended in Mar. 2026 was €-3.37 Mil. Palisade Bio's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Palisade Bio's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Palisade Bio's current OCF Yield % is -3.99%.

The historical rank and industry rank for Palisade Bio's OCF Margin % or its related term are showing as below:


During the past 6 years, the highest OCF Margin % of Palisade Bio was -4453.20%. The lowest was -4453.20%. And the median was -4453.20%.

FRA:7NS0's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Palisade Bio OCF Margin % Related Terms

Palisade Bio OCF Margin % Historical Data

* Premium members only.

The historical data trend for Palisade Bio's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palisade Bio OCF Margin % Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 -4,458.08 0.00 0.00

Palisade Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:7NS0
35GF Score
Palisade Bio Inc FRA:7NS0
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palisade Bio OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Palisade Bio's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-9.263/0
= %

Palisade Bio's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.365/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Palisade Bio (FRA:7NS0) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Palisade Bio and its competitors. According to the industry distribution chart, Palisade Bio ranks #999999 out of 959 companies in the Biotechnology industry.
Is Palisade Bio's OCF Margin % too high?
Palisade Bio's current OCF Margin % is 0.00%. Based on the distribution chart, Palisade Bio ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Palisade Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Palisade Bio's OCF Margin % compare to PBYI and NWBO?
According to the Biotechnology industry distribution chart, Palisade Bio ranks #999999 out of 959 companies for OCF Margin %. This places Palisade Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Palisade Bio and its competitors. Palisade Bio's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palisade Bio stock overvalued right now?
Palisade Bio (FRA:7NS0) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Palisade Bio's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Palisade Bio (FRA:7NS0), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palisade Bio Business Description

Other Exchanges PALI:USA
Address 4600 South Syracuse Street, Suite 900, Denver, CO, USA, 80237
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
35GF Score

Get the complete analysis for FRA:7NS0

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.01
Price